The Vanguard Group 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:00 pm Purchase |
2023-12-29 | 13G | Celldex Therapeutics, Inc. CLDX |
The Vanguard Group | 3,046,331 5.570% |
532,767 (+21.20%) |
Filing |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | Celldex Therapeutics, Inc. CLDX |
The Vanguard Group | 2,513,564 5.340% |
100,508 (+4.17%) |
Filing |
| 2022-02-09 3:33 pm Purchase |
2021-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
The Vanguard Group | 2,413,056 5.170% |
2,413,056 (New Position) |
Filing |